Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAB-21822 Combined With Second Line Chemotherapy and Bevacizumab for Metastatic Colorectal Cancer With KRAS G12C Mutation
NCT06838338Phase 1Active, not recruiting
- Start
- Mar 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of glecirasib in colorectal cancer (CRC). Primary endpoint: Objective Response Rate at 1 year. Started Mar 2025; status: active, not recruiting.
02
Drugs
glecirasib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06838338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06838338.